Skip to main content
Peter Martin, MD, Oncology, New York, NY, New York-Presbyterian Hospital

PeterMartinMD

Oncology • New York, NY

Hematologic Oncology

Associate Professor, Medicine, Weill Cornell Medicine

Request Appointment

Overview of Dr. Martin

I take care of people with lymphoma. I don't rush, I listen. Together we will develop the plan that is best. At the Weill Cornell Lymphoma Program, one of the most experienced teams in the country, we work along side experts in every field of medicine to care for the whole person.

As Chief of the Lymphoma Program, I know that our group is working tirelessly to develop better treatments and integrate them into clinical practice. We have been involved in the development of virtually every drug approved for treatment of lymphoma over the past 15 years, including targeted therapies and immunotherapy. We have made a lot of progress, and we are not stopping to rest.

Education & Training

  • McGill University
    McGill UniversityFellowship in Hematology, 2004 - 2006
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
  • University of Alberta
    University of AlbertaClass of 2001
  • Cornell University
    Cornell UniversityMS

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • NY State Medical License
    NY State Medical License 2009 - 2026
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)
    Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
    Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Press Mentions

  • Who Qualifies for a Coronavirus Booster Shot? Why It’s Still Unclear
    Who Qualifies for a Coronavirus Booster Shot? Why It’s Still UnclearAugust 13th, 2021
  • The Complex Situation for Immunocompromised People and COVID-19 Vaccines
    The Complex Situation for Immunocompromised People and COVID-19 VaccinesJune 16th, 2021
  • Assessing Response to Follicular Lymphoma Treatment
    Assessing Response to Follicular Lymphoma TreatmentSeptember 24th, 2020
  • Join now to see all

Professional Memberships

Other Languages

  • Spanish, French

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    Healthfirst New York
    Humana ChoiceCare Network PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Peter Martin, Dr. Peter Martin, MD, Dr. P Martin